Phase 1
Completed N=30
This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood
Healthy
Source: ClinicalTrials.gov NCT03259490 ↗
Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Feb 2020
Primary outcomePrimary: Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) for Empagliflozin — 5656.07; 5488.31 nanomoles*hours/ litres (nmol*h/L)
Summary
To establish the bioequivalence of one fixed dose combination (FDC) tablet of empagliflozin/linagliptin/metformin extended release (XR) versus the free combination of empagliflozin tablet, linagliptin tablet, and metformin XR tablets administered as a single dose under fed conditions
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) for Empagliflozin |
5656.07; 5488.31 | — |
| PRIMARY AUC0-tz for Metformin. |
12455.82; 12412.57 | — |
| PRIMARY Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to 72 Hours (AUC0-72) for Linagliptin |
238.84; 238.11 | — |
| PRIMARY Maximum Measured Concentration of the Empagliflozin in Plasma (Cmax) |
540.01; 540.26 | — |
| PRIMARY Cmax for Metformin in Plasma |
1237.16; 1147.88 | — |
| PRIMARY Cmax for Linagliptin in Plasma |
5.69; 5.86 | — |
| SECONDARY Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity) for Empagliflozin (AUC(0-∞) |
5727.20; 5554.37 | — |
| SECONDARY AUC(0-∞) for Metformin |
12745.62; 12724.27 | — |
| SECONDARY AUC(0-∞) for Linagliptin |
384.27; 394.95 | — |
Eligibility Criteria
Inclusion Criteria
- Healthy male or female subjects according to the assessment of the investigator, based on a complete medical history including a physical examination, vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead Electrocardiogram (ECG), and clinical laboratory tests
- Age of 18 to 55 years (incl.)
- BMI of 18.5 to 29.9 kg/m2 (incl.)
- Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and local legislation
- Female subjects of childbearing potential willing to use adequate contraception.
- Further inclusion criteria apply
Exclusion Criteria
- Any finding in the medical examination (including Blood Pressure (BP), Pulse Rate (PR), or Electrocardiogram (ECG)) is deviating from normal and judged as clinically relevant by the investigator
- Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 beats per minute (BPM)
- Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
- Any evidence of a concomitant disease judged as clinically relevant by the investigator
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological, or hormonal disorders
- Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
- Further exclusion criteria apply
Data sourced from ClinicalTrials.gov (NCT03259490). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.